Shaheen R A, Zazgornik J, Kuska J, Kokot F, Schneider J
2nd Department of Internal Medicine, General Hospital Linz, Austria.
Int J Clin Pharmacol Ther Toxicol. 1990 Nov;28(11):480-6.
Cimetidine pharmacokinetics was investigated in four groups: Group I with three normals (serum creatinine less than 1.5 mg/dl), Group II with three kidney patients, renal function slightly impaired (serum creatinine greater than 1.8-4.3 mg/dl), Group III with three patients suffering from severe impairment (serum creatinine greater than 4.3 mg/dl) and Group IV with three patients on chronic hemodialysis. All four groups were given cimetidine retard (350 mg tablets Neutronorm retard, Ebewe Arzneimittel GmbH, A-4866 Unterach a.A., Austria). Groups I and II (normals and slightly impaired renal function) received the tablets twice a day with an interval of 12 h (7:00 a.m. and 7:00 p.m.). Groups III and IV (severely impaired renal function and hemodialysis patient were only given one dose a day (7:00 a.m.). The group of normals (I) and the group with slightly impaired renal function (II) had the highest serum cimetidine concentrations one to two h after the morning dose, followed by an exponential decrease. After the evening dose in Group I, the highest concentrations were found after 4 h. Group II had the highest concentrations four to eight h after administration. Compared to the morning dose, the exponential decrease of the serum cimetidine concentration was delayed in onset and slower in phasing out. Furthermore, concentration was higher during the night than during the day.(ABSTRACT TRUNCATED AT 250 WORDS)
第一组有三名正常人(血清肌酐低于1.5mg/dl),第二组有三名肾功能轻度受损的肾病患者(血清肌酐大于1.8 - 4.3mg/dl),第三组有三名严重受损患者(血清肌酐大于4.3mg/dl),第四组有三名接受慢性血液透析的患者。所有四组均服用缓释西咪替丁(350mg片剂Neutronorm retard,奥地利埃贝韦制药有限公司,奥地利下阿赫A - 4866)。第一组和第二组(正常人及肾功能轻度受损者)每天服用两次片剂,间隔12小时(上午7:00和晚上7:00)。第三组和第四组(肾功能严重受损者及血液透析患者)每天仅服用一剂(上午7:00)。正常组(第一组)和肾功能轻度受损组(第二组)在早晨服药后1至2小时血清西咪替丁浓度最高,随后呈指数下降。第一组晚上服药后,4小时后浓度最高。第二组在给药后4至8小时浓度最高。与早晨剂量相比,血清西咪替丁浓度的指数下降起始延迟且逐渐消失较慢。此外,夜间浓度高于白天。(摘要截断于250字)